Heidelberg, Feb15th:
At the Cellzome anniversary reception at the European Molecular Biology Laboratory (EMBL) Julia Schaft introduced in the solemn speach Cellzome as the first and foremost spin-out story.
As a spin-off from the EMBL, Cellzome originally came from the academic world and was admitted to the global research network GSK in 2012. As a result, the company was able to grow stronger and faster with better transfer research findings to healthcare.
"The embedding in one of the most flourishing European biotech regions in the life science network around Heidelberg is crucial for the success of Cellzome. The density of research institutes, top universities, start-ups and global pharmaceutical companies is reflected in the more than 140 members of the local BioRN network, which represents a unique interface between academic institutions, the pharmaceutical industry and politics. Our initiatives aim to establish and expand connections and interactions with regional innovation actors as well as with innovation regions worldwide in order to create successful knowledge development and transfer," says Dr. Julia Schaft, Managing Director BioRN.